scholarly journals Defining racial disparities across the prostate cancer disease continuum in an equal access-to-care setting within the Nation’s largest Veterans Affairs healthcare network

Author(s):  
Kosj Yamoah
JAMA Oncology ◽  
2019 ◽  
Vol 5 (12) ◽  
pp. 1809
Author(s):  
Travis Gerke ◽  
Shivanshu Awasthi ◽  
Kosj Yamoah

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 6119-6119
Author(s):  
D. Crockett ◽  
W. Gonsalves ◽  
T. Tashi ◽  
I. Aldoss ◽  
A. R. Sama ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e19037-e19037
Author(s):  
Ravi Bharat Parikh ◽  
Kyle William Robinson ◽  
Sumedha Chhatre ◽  
Elina Medvedeva ◽  
S. Bruce Malkowicz ◽  
...  

e19037 Background: Equal access to care may mediate racial disparities among men with localized prostate cancer. We examined the association between African-American race and long-term mortality among men with high-risk prostate cancer in a large equal-access health system. Methods: In this retrospective cohort study, we used the VA Corporate Data Warehouse to identify African-American (AA) and non-Hispanic White Veterans diagnosed with high-risk (prostate-specific antigen [PSA] ≥ 20 ng/mL, Gleason 8-10, or stage ≥ cT2c) localized prostate cancer between January 1st, 2001 and December 31st, 2011 and followed through January 1st, 2019. Veterans who did not receive continuous VA care were excluded. We used descriptive statistics to compare type of therapy received and multivariable Cox proportional hazards regressions to estimate the association between mortality and race. Cox models were adjusted for age, pre-treatment PSA, year of diagnosis, enrollment priority (an individual-level proxy for income and disability need), marital status, Elixhauser comorbidity index, and primary treatment. Results: Among 14,877 Veterans (median age 67 years [interquartile range [IQR] 62-75]), 4,160 (28.0%) were AA. Median followup was 9.0 years (IQR 6.1-11.4). Compared to White men, AA men were more likely to have PSA ≥ 20 (49.9% vs. 40.9%), be unmarried (59.3% vs. 43.3%), have ≥3 comorbidities (46.4% vs. 41.0%), and have high disability and income need (22.0% vs. 18.6%) (all p < 0.001). Over time, AA Veterans were consistently less likely to receive prostatectomy (18.9% vs. 24.9%). Crude mortality rates were 50.6 and 61.6 deaths per 1000 patient-years for AA and White Veterans, respectively. After adjusting for all covariates, AA Veterans had lower all-cause mortality (adjusted hazard ratio [aHR] 0.83, 95% CI 0.79-0.88, p < 0.001) compared to White Veterans. This association was consistent across pre-specified subgroups (Table). Conclusions: Among men with high-risk prostate cancer who received continuous care within a large equal-access health system, African-Americans had lower all-cause mortality compared to Whites. Equal access to care may mitigate or reverse traditional racial disparities in mortality among men with prostate cancer. [Table: see text]


2008 ◽  
Vol 45 (3) ◽  
pp. 211-214 ◽  
Author(s):  
Joseph P. Forester ◽  
Bruce A. Ong ◽  
André Fallot

JAMA Oncology ◽  
2019 ◽  
Vol 5 (12) ◽  
pp. 1810
Author(s):  
Robert T. Dess ◽  
Brandon A. Mahal ◽  
Daniel E. Spratt

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 199-199
Author(s):  
I. Al-Howaidi ◽  
L. Shatat ◽  
T. Tashi ◽  
W. Gonsalves ◽  
P. T. Silberstein ◽  
...  

199 Background: Epidemiological studies have demonstrated that African-American (AA) men with prostate cancer have lower overall survival and cancer-specific survival rates than Caucasian (CA) men with prostate cancer. We aim to assess whether racial disparities exist for prostate cancer within an equal access health care system like the Veterans Affairs (VA) hospitals. Methods: A retrospective analysis of AA and CA with metastatic prostate adenocarcinoma diagnosed between 1995 to 2007 via the Veterans Affairs Central Cancer Registry was conducted. Age, Race and type of treatment received were studied with respect to overall survival by using log-rank and Kaplan-Meier analysis. Results: A total of 8,195 patients with advanced prostate cancer were analyzed, majority of them where CA (66.32%), 30.8% were AA and 2.8% belonged to other races. The median survival for AA was 2.71 years, 2.88 years in CA and 4.02 years in other races (P value <0.0001). Subgroup analysis based on treatment modality used showed the following median survival rates in years: No treatment (CA: 1.73, AA: 1.39, other races: 3.79, P<0.816), Hormonal therapy alone (CA: 2.51,AA: 2.45, Others:3.72, P<0.022), Radiation therapy alone (CA: 2.2, AA: 2.7, Others: 2.26, P<0.832), combined hormone and radiation therapy (CA: 2.71, AA: 2.31, Others: 6.64, P<0.029). However when CA and AA survival were compared excluding other races there was no statistically significant difference in survival irrespective of type of therapy received. Conclusions: In advanced prostate cancer, AA and CA have uniformly poor prognosis. Type of therapy received did not influence the survival of both races. The numbers for other races is too small to make a definitive conclusion regarding their prognosis. No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document